The number of patients with melanoma, renal cell carcinoma, and anti‐CTLA‐4 plus anti‐PD‐1 combination therapy in the irAE group was substantially higher than in the non‐irAE group, whereas the number of patients with gastric cancer, urothelial carcinoma, and anti‐PD‐1 monotherapy in the irAE group was markedly lower than in the non‐irAE group (Table 1). The gene discussed is CTLA4; the disease is renal cell carcinoma.